Phase 2/3 Dose-Ranging Study of the Safety and Efficacy of OTX-101 in the Treatment of Keratoconjunctivitis Sicca

A Randomized, Multicenter, Double-Masked, Vehicle-Controlled, Dose-Ranging Study of the Safety and Efficacy of OTX-101 in the Treatment of Keratoconjunctivitis Sicca

Status

Completed

Phases

Phase 2Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02254265

Enrollment

455

Registered

2014-10-01

Start date

2014-09-30

Completion date

2015-05-31

Last updated

2022-08-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dry Eye Disease, Keratoconjunctivitis Sicca

Brief summary

This is a Phase 2/3 study to evaluate the safety and efficacy of 2 different dose concentrations of OTX-101 dosed twice a day in both eyes for 84 days compared to placebo (vehicle) in patients with keratoconjunctivitis sicca (dry eye disease).

Detailed description

Keratoconjunctivitis sicca (KCS) is a common multifactorial ophthalmologic disorder of the tears and ocular surface characterized by symptoms of burning, stinging, itching, grittiness, scratchiness, foreign body sensation, dryness, stickiness and tired eye sensation. This study is the first clinical safety and efficacy study with OTX-101 and is designed to compare two dose concentrations of OTX-101 against vehicle (placebo) in reducing the signs and symptoms of KCS and evaluate safety when dosed twice a day in both eyes over an 84 day period.

Interventions

DRUGOTX-101 0.05%

OTX-101 0.05% Ophthalmic Solution

DRUGOTX-101 0.09%

OTX-101 0.09% Ophthalmic Solution

DRUGVehicle

Vehicle of OTX-101 Ophthalmic Solution

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

1. Subjects age 18 years or older on the date of informed consent. 2. All subjects must provide signed written consent prior to participation in any study-related procedures. 3. Patient-reported history of KCS for a period of at least 6 months. 4. Clinical diagnosis of bilateral KCS supported by OTX-101-2014-001 study assessments. 5. Lissamine green conjunctival staining sum score of ≥ 3 to ≤ 9 out of a total possible score of 12 (scoring excludes superior zones 2 and 4) in the same eye at Screening and Baseline. 6. Global symptom score ≥ 40 at both Screening and Baseline. 7. Corrected Snellen VA of better than 20/200 in each eye. 8. Willing to discontinue use of current dry eye therapy (including artificial tears or ocular lubricants) during the study as of the run-in period. 9. Female subjects of childbearing potential must have a negative urine pregnancy test at Screening. Women of childbearing potential (ie, women who are not either postmenopausal for one year or surgically sterile) must use an acceptable form of contraception throughout the study.

Exclusion criteria

1. Use of cyclosporine ophthalmic emulsion 0.05% (Restasis®) within 3 months prior to Screening. 2. Previous treatment failure (lack of efficacy) on cyclosporine ophthalmic emulsion 0.05% (Restasis). 3. Diagnosed with Sjögren's disease ˃5 years prior to Screening. 4. Clinical diagnosis of seasonal and perennial allergic conjunctivitis. 5. Use of systemic and topical medications that are known to cause dry eye within 7 days prior to Screening and throughout the study period. These include the following medications: * Immunomodulators (permitted if dose is stable for 3 months prior to screening and does not change during the study period) * Antihistamines (including over-the counter (OTC)) * Cholinergics * Antimuscarinics * Tricyclic antidepressants * Phenothiazines * Retinoids 6. Oral omega-3 fatty acids (permitted if dose is stable for 3 months prior to Screening and does not change during the study period) 7. Use of any topical ophthalmic medications, prescription (including antiglaucoma medications) or OTC (including artificial tears), other than the assigned study medication during the study period. 8. Current active eye disease other than KCS (i.e., any disease for which topical or systemic ophthalmic medication is necessary). 9. History of herpes keratitis. 10. Unstable macular disease (e.g., age-related macular degeneration, diabetic maculopathy). Stable macular disease is defined as no reduction in central VA within 6 months prior to Screening. 11. Diagnosis of chronic uveitis. 12. Corneal transplant (e.g., penetrating keratoplasty, lamellar keratoplasty, Descemet's stripping endothelial keratoplasty (DSEK) ). 13. Corneal refractive surgery (e.g., laser-assisted in situ keratomileusis (LASIK\]) photo refractive keratectomy (PRK), limbal relaxing incision (LRI) ) within 6 months prior to screening or postoperative refractive surgery symptoms of dryness that have not resolved. 14. Cataract surgery within 3 months prior to Screening. 15. Non-laser glaucoma surgery at any time; glaucoma laser procedures within 3 months prior to Screening. 16. Presence of punctal plugs or past history of permanent punctal occlusion (e.g., cautery). 17. Lagophthalmos or clinically significant eyelid margin irregularity of the study eye whether congenital or acquired. 18. Presence of conjunctivochalasis (i.e., mechanical blockage of the lower lid punctum by redundant conjunctiva). 19. Presence of pterygium in the study eye. 20. Unwilling to discontinue use of contact lenses during the duration of the study. 21. Preplanned elective surgery or hospitalization during the study period. 22. HIV-positive. 23. Unable to reliably report symptoms and history. 24. Has known hypersensitivity or contraindication to the study medication(s) or their components. 25. Has a history or presence of chronic generalized systemic disease that the Investigator feels might increase the risk to the subject or confound the result(s) of the study. 26. Has a severe/serious ocular condition, or any other unstable medical condition that, in the Investigator's opinion, may preclude study treatment or follow-up. 27. Women who are pregnant or breastfeeding. 28. Participation in any drug or device clinical investigation within 30 days prior to entry into this study and/or during the period of study participation. 29. Previous randomization into this study.

Design outcomes

Primary

Measure	Time frame	Description
Conjunctival Staining	Baseline to 84 days	Mean change from baseline at day 84 for the lissamine green conjunctival staining score in the designated study eye. The Investigator recorded a score for each area of each eye on a 0 (No punctate stain in zone) to 3 (Densely concentrated micropunctate stain spots) scale
Global Symptom Score	Baseline to 84 days	Mean change from baseline at day 84 for the global symptom score. The freuency and severy of dry eye and irritation scores were used to calculate symptom score as follows: Frequency of dry eye/irritation based on a scale of 0 (rarely) to 100 (all the time) Severity of dryness or irritation based on a scale of 0 (very mildly) to 100 (very severe). The global symptom score was calculated as the square root of the frequency score times the severity score

Secondary

Measure	Time frame	Description
Tear Film Break up Time (TBUT)	Baseline to 84 days	Mean change from baseline in TBUT in the study eye from baseline at Day 84
Corneal Staining Score	Baseline to 84 days	Mean Change from Baseline in Corneal Staining Score in the Study Eye. Expanded National Eye Institute Scale for Corneal Staining Score was used to grade each of the 5 areas of the cornea on a 0 (No punctate stain in area) to 4 (Severe diffuse (coalescent) macropunctate stain of the area) scale
Schirmer's Test	Baseline to 84 days	Change from Baseline in Categorized Schirmer's Test Score. Schirmer's test was performed with strips placed in both eyes at the same time. Strips were removed after 5 minutes and the amount of wetting (in mm) was recorded as scores from 1 to 5. 1: \< 3 mm, 3 - 6 mm, 7 - 10 mm, 11 - 14 mm, and 5: \> 14 mm
Patient Satisfaction	Baseline to 84 days	Patient satisfaction with treatment score using 5-point scale (1=extremely dissatisfied to 5=extremely satisfied)

Countries

United States

Participant flow

Participants by arm

Arm	Count
OTX-101 0.05% OTX-101 0.05% ophthalmic solution 1 drop in both eyes BID for 84 days OTX-101 0.05%: OTX-101 0.05% Ophthalmic Solution	151
OTX-101 0.09% OTX-101 0.09% ophthalmic solution 1 drop in both eyes BID for 84 days OTX-101 0.09%: OTX-101 0.09% Ophthalmic Solution	152
Vehicle Vehicle of OTX-101 ophthalmic solution 1 drop in both eyes BID for 84 days Vehicle: Vehicle of OTX-101 Ophthalmic Solution	152
Total	455

Baseline characteristics

Characteristic	OTX-101 0.05%	OTX-101 0.09%	Vehicle	Total
Age, Continuous	61.9 years STANDARD_DEVIATION 13.27	59.2 years STANDARD_DEVIATION 14.55	59.3 years STANDARD_DEVIATION 13.75	60.1 years STANDARD_DEVIATION 13.9
Race (NIH/OMB) American Indian or Alaska Native	1 Participants	0 Participants	0 Participants	1 Participants
Race (NIH/OMB) Asian	8 Participants	7 Participants	3 Participants	18 Participants
Race (NIH/OMB) Black or African American	11 Participants	13 Participants	20 Participants	44 Participants
Race (NIH/OMB) More than one race	3 Participants	6 Participants	7 Participants	16 Participants
Race (NIH/OMB) Native Hawaiian or Other Pacific Islander	0 Participants	0 Participants	2 Participants	2 Participants
Race (NIH/OMB) Unknown or Not Reported	0 Participants	0 Participants	0 Participants	0 Participants
Race (NIH/OMB) White	128 Participants	126 Participants	120 Participants	374 Participants
Sex: Female, Male Female	119 Participants	122 Participants	120 Participants	361 Participants
Sex: Female, Male Male	32 Participants	30 Participants	32 Participants	94 Participants

Adverse events

Event type	EG000 affected / at risk	EG001 affected / at risk	EG002 affected / at risk
deaths Total, all-cause mortality	0 / 152	0 / 151	0 / 152
other Total, other adverse events	37 / 151	31 / 152	30 / 152
serious Total, serious adverse events	1 / 152	0 / 151	4 / 152

Outcome results

Primary

Conjunctival Staining

Mean change from baseline at day 84 for the lissamine green conjunctival staining score in the designated study eye. The Investigator recorded a score for each area of each eye on a 0 (No punctate stain in zone) to 3 (Densely concentrated micropunctate stain spots) scale